XenoPort can give no assurance with respect to these statements and we assume no obligation to update them. For detailed information about the risks and uncertainties that could cause actual results to differ materially from those implied by or anticipated in these forward-looking statements, please refer to the Risk Factor section of our most recent SEC filings, including our discussion of the inherent risks of clinical trials and regulatory matters. This webcast is a copyright of XenoPort.At this time, I will turn the presentation over to Ron. Ron Barrett Thank you, Jackie. Good afternoon and thank you to those joining us on today’s call. I would like to discuss our progress since the last quarterly call and then Bill Harris will discuss the highlights of our second quarter financial results. We will both be relatively brief and then we will then take your questions. We have been busy since the start of the second quarter and I’d like to thanks Xenoport’s employees for their strong efforts in advancing multiple development programs and other business objectives. Starting with our novel fumarate compound, 829, we initiated the first human trial two weeks ago. We expect dosing of the 60 healthy volunteer subjects in this single dose fed versus fasted Phase 1 trial four formulations of 829 plus placebo will be completed this week. We will have a lot of bioanalytical work to complete and we hope to report preliminary safety, tolerability, pharmacokinetic results from this trial in October. As you know, we are interested in the potential development of 829 in relapsing-remitting multiple sclerosis or RRMS and psoriasis. In addition to these two potential indications, there are published data that suggest potential utility of Nrf2 activator in a number of neurodegenerative diseases. In July, we were happy to announce the collaboration with the Michael J. Fox Foundation that will enable us to assess 829’s potential efficacy in the Parkinson's disease animal model.